- Sernova’s (SVA) share price shot up this morning, after it unveiled early stage findings from a trial of its patented Cell Pouch treatment
- At a recent conference, trial lead Dr. Witkowski spoke about the Cell Pouch system and how it shows sustained clinical benefits for patients with type 1 diabetes
- One patient was eventually provided a single infusion of islets
- This patient is now insulin free and has been for nine months with optimal glucose control
- Sernova (SVA) is up 55.65 per cent and is currently trading at C$1.93 per share at 1:30pm EST
Sernova’s (SVA) share price shot up this morning, after it unveiled early stage findings from a trial of its patented Cell Pouch treatment.
The company’s goal is to develop a “functional cure” to improve the lives of people dealing with a chronic disease such as diabetes.
Sernova is conducting a phase I/II non-randomized, unblinded, company-sponsored trial. This will allow them to safely assess the tolerability of islet transplantation into the patented Cell Pouch.
All patients are diabetic subjects with hypoglycemia unawareness. They also have an inability to producer their own insulin.
The secondary objective is to assess the efficacy through a series of defined measures.
During the conference on January 15, 2020, Dr. Witkowski spoke about the Cell Pouch System and how it shows sustained clinical benefits for patients with type 1 diabetes.
Currently, five of seven patients are currently enrolled in the study and have been implanted with the Cell Pouch. Three of seven patients have received their first/one islet transplant, while two of seven patients have received their first and second islet transplant.
The remaining two patients are actively being pre-scanned to complete trial enrolment.
With the positive clinical benefit achieved in patients with said cell pouch islets. One patient was eventually provided a single infusion of islets. This top up to the islets contributed to this patient achieving and sustaining insulin independence.
This patient is now insulin free and has been for nine months with optimal glucose control. Dr. Witkowski is pleased about the additional preliminary clinical trial results.
“While we continue to validate the therapeutic potential of Sernova’s Cell Pouch with islets for type 1 diabetes, we also continue to optimize conditions within the designed clinical protocol towards a therapy to provide to diabetic patients,” he said.
“I am excited to be part of this evolution in patient treatment as we advance the Cell Pouch cell therapy approach towards a functional cure for diabetes,” he added.
Sernova is up 55.65 per cent and is currently trading C$1.93 per share at 1:30 PM EST.
